Veritas Pharma Performance
| VRTHFDelisted Stock | USD 0 0.00 0.00% |
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Veritas Pharma are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Veritas Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable technical indicators, Veritas Pharma is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 481.00 | |
| Total Cashflows From Investing Activities | 386.00 |
Veritas |
Veritas Pharma Relative Risk vs. Return Landscape
If you would invest 0.15 in Veritas Pharma on November 1, 2025 and sell it today you would earn a total of 0.00 from holding Veritas Pharma or generate 0.0% return on investment over 90 days. Veritas Pharma is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Veritas, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Veritas Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Veritas Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Veritas Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Veritas Pharma is not yet fully synchronised with the market data | |
| Veritas Pharma has some characteristics of a very speculative penny stock | |
| Veritas Pharma has a very high chance of going through financial distress in the upcoming years | |
| Veritas Pharma has accumulated 765.63 K in total debt with debt to equity ratio (D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. Veritas Pharma has a current ratio of 0.63, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Veritas Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Veritas Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Veritas Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Veritas to invest in growth at high rates of return. When we think about Veritas Pharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (2.29 M) with loss before overhead, payroll, taxes, and interest of (112.96 K). | |
| Veritas Pharma has accumulated about 125.27 K in cash with (294.86 K) of positive cash flow from operations. | |
| Roughly 27.0% of Veritas Pharma outstanding shares are owned by insiders |
Veritas Pharma Fundamentals Growth
Veritas Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Veritas Pharma, and Veritas Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Veritas Pink Sheet performance.
| Return On Equity | -5.67 | |||
| Return On Asset | -0.21 | |||
| Current Valuation | 1.77 M | |||
| Shares Outstanding | 71.14 M | |||
| Price To Earning | 0.20 X | |||
| Price To Book | 0.43 X | |||
| EBITDA | (491.67 K) | |||
| Cash And Equivalents | 125.27 K | |||
| Total Debt | 765.63 K | |||
| Debt To Equity | 0.05 % | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (294.86 K) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 730 | |||
About Veritas Pharma Performance
By analyzing Veritas Pharma's fundamental ratios, stakeholders can gain valuable insights into Veritas Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Veritas Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Veritas Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Indigenous Bloom Hemp Corp. focuses on the production of hemp products for commercial use. It sells hemp biomass and flowers, as well as phytocannabinoid rich extracts derived from hemp biomass. Indigenous Bloom is traded on OTC Exchange in the United States.Things to note about Veritas Pharma performance evaluation
Checking the ongoing alerts about Veritas Pharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Veritas Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Veritas Pharma is not yet fully synchronised with the market data | |
| Veritas Pharma has some characteristics of a very speculative penny stock | |
| Veritas Pharma has a very high chance of going through financial distress in the upcoming years | |
| Veritas Pharma has accumulated 765.63 K in total debt with debt to equity ratio (D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. Veritas Pharma has a current ratio of 0.63, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Veritas Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Veritas Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Veritas Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Veritas to invest in growth at high rates of return. When we think about Veritas Pharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (2.29 M) with loss before overhead, payroll, taxes, and interest of (112.96 K). | |
| Veritas Pharma has accumulated about 125.27 K in cash with (294.86 K) of positive cash flow from operations. | |
| Roughly 27.0% of Veritas Pharma outstanding shares are owned by insiders |
- Analyzing Veritas Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Veritas Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Veritas Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Veritas Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Veritas Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Veritas Pharma's pink sheet. These opinions can provide insight into Veritas Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in Veritas Pink Sheet
If you are still planning to invest in Veritas Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Veritas Pharma's history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |